Correspondence : Huaijun Liu (lhj6254@foxmail.com) Aberrant expression of Fos-related antigen-1 (Fra1) is commonly elevated in various malignant cancers and is strongly implicated in invasion and metastasis. However, the molecular mechanisms underlying its dysregulation in human glioma remain poorly understood. In the present study, we demonstrate that up-regulation of Fra1 plays a crucial role in the glioma aggressiveness and epithelial-mesenchymal transition (EMT) activated by Wnt/β-catenin signal pathway. In glioma cells, activation of Wnt/β-catenin signalling by Wnt3a administration obviously induced EMT and directly activated the transcription of Fra1. Phenotype experiments revealed that up-regulation of Fra1 induced by Wnt/β-catenin signalling drove the EMT of glioma cells. Furthermore, it was found that the cisplatin resistance acquired by Wnt/β-catenin signalling activation depended on increased expression of Fra1. Analysis of clinical specimens verified a positive correlation between Fra1 and β-catenin as well as a poor prognosis in glioma patients with double-high expressions of them. These findings indicate that an aberrant Wnt/β-catenin signalling leads to the EMT and drug resistance of glioma via Fra1 induction, which suggests novel therapeutic strategies for the malignant disease.
Introduction
Among various human cancers, malignant glioma (MG) is one of the most aggressive tumours and occurs frequently in the central nervous system [1] . MG often results in a high mortality rate and poor prognosis because of its highly invasive and infiltrative character [2] . In most cases, lethality in glioma patients is caused by metastasis involving migration and invasion of cancer cells, which results in resistance to the existing drugs [3] . Although many studies have demonstrated the knowledge of invasive and infiltrative properties in glioma, the mechanisms for metastasis are still not well determined but necessary for prognosis and treatment.
Numerous factors and signal pathways associated with the invasion and migration of glioma cancer have been found in previous studies [4] . Among them, epithelial-mesenchymal transition (EMT), which reduces epithelial markers (E-cadherin) and increases mesenchymal markers (N-cadherin and Vimentin), leads to an increased invasive or metastatic phenotype in glioma cells [5] . Besides, it has been reported that the EMT-related transcription factors (EMT-TFs) including Slug, Snail, ZEB1 and Twist are indispensable for EMT process [6] [7] [8] [9] . As another important factor, Fos-related antigen-1 (Fra1) always indicates metastasis and poor prognosis in a variety of human cancers. Different from other members of the Fos family, Fra1 is closely related with the motile and invasive phenotypes of cancer cells [10] . Mesenchymal characteristics and morphological changes could be induced by overexpression of Fra1 [11] . More recently, Fra1 has been demonstrated as a gatekeeper of the EMT programme during cancer progression [12, 13] . However, the mechanism for Fra1 regulation in glioma remains unclear.
The Wnt/β-catenin pathway plays a critical role in many biological processes such as cell survival, proliferation, migration and polarity [14] . Aberrant activation of Wnt/β-catenin signalling has been observed in a variety of human cancers including glioma. At the molecular level, Wnt ligands interact with Fzd/LRP that induce the translocation of β-catenin from cytoplasm to nucleus. The nucleus-accumulated β-catenin functions as a transcriptional co-activator with Tcf/Lef and then regulates the expressions of target genes such as c-Myc, cyclin D1 and matrix metalloproteinases (MMPs) [15, 16] . β-catenin, a key signal transducer of Wnt pathway, is overexpressed in glioma and knockdown of it reduces the invasiveness of glioma cells [17] . Although previous findings confirmed Wnt/β-catenin signalling as a metastasis driver in glioma, more target genes need to be identified to better understand the pathway [18] .
In the present study, Fra1 is identified as a target of Wnt/β-catenin signalling and then mediates EMT as well as cisplatin resistance in glioma cells. Further clinical analysis reveals that Fra1 is positively correlated with β-catenin and glioma progression, which confirms a critical role of Wnt/β-catenin/Fra1 signalling axis in glioma aggressiveness.
Materials and methods

Cell culture and treatment
Human glioma cell lines U-251 and U-87 were purchased from the American Type Culture Collection (ATCC) and cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% FBS (Gibco), 100 U/ml penicillin and 100 mg/ml streptomycin at 37
• C in a humidified atmosphere with 5% CO 2 . For lithium chloride (LiCl) or CHIR99021 treatment, cells were cultured to approximately 40% confluence and then treated with 20 mM LiCl or 3 μM CHIR99021. Transfections of plasmids and siRNA were performed using Lipofectamine 2000 transfection reagent (Life Technologies) according to the manufacturer's instructions. Stable transfections of Wnt3a and shFra1 were maintained by G418.
Plamids, siRNA and antibodies
The constructs encoding Flag-tagged Fra1 and Wnt3a were cloned into pcDNA3.0 vector. The siRNA (sc-35405) and shRNA (sc-35405-SH) targeting Fra1 were obtained from Santa Cruz Biotechnology. Antibodies against E-cadherin (sc-59780), Fibronectin (sc-69681), Vimentin (sc-73259), ZO-1 (sc-8146), Fra1 (sc-48424), Zeb2 (sc-271984), β-catenin (sc-31001) and GAPDH (sc-51907) were from Santa Cruz. Antibodies against Twist1 (ab50581), Zeb1 (ab124512), Snail (ab53519), Slug (ab27568) were from Abcam.
Quantitative real-time PCR analysis
Isolation of total RNA from cells was performed using RNAiso Plus (TaKaRa). The purity and concentration of RNA samples were determined by NanoDrop Spectrophotometer (NanoDrop). Reverse transcription was carried out with the PrimeScript RT reagent kit (TaKaRa). Real-time quantitative PCR was achieved using SYBR Select Master Mix (Roche) according to the manufacturer's instructions. Target gene expression was normalized to actin levels in respective samples as an internal control and the results are representative of at least three independent experiments.
Western blot
Cells were harvested and lysed using Ripa lysis buffer (50 mM Tris/HCl, pH 7.4, 100 mM 2-mercaptoethanol, 2% w/v SDS, 10% glycerol). The protein concentration was determined with the Bradford method (Bio-Rad). The proteins were separated by 10% SDS/PAGE and transferred to nitrocellulose membranes (Whatman). The membranes were incubated with dilutions of primary antibodies followed by IRDye 800CW or IRDye 680-conjugated secondary antibodies and then detected by the Odyssey Infrared Imaging System (Li-COR).
Luciferase reporter assay
The promoter fragments of human Fra1 were amplified by PCR and cloned into the pGL3 vector. The reporter constructs containing different lengths of Fra1 promoter or mutated Tcf/Lef-binding sites were generated by subsequent PCR-based cloning. A pair of luciferase reporter constructs, TOPflash and FOPflash, was used to evaluate Tcf/Lef transcriptional activity. TOPflash contains three copies of TCF-4-binding sites and FOPflash contains mutated TCF-4-binding sites. The pRL-SV40 vector was cotransfected with the reporter constructs in each experiment as an internal control for transfection efficiency. After transfection for 24 h, cells were treated with 200 ng/ml Wnt3a for 12 h and luciferase activities were measured using the Dual-Luciferase Reporter Assay System (Promega). All experiments were performed in triplicate.
Xenograft tumour assay
In vivo chemosensitivity experiment was performed by the subcutaneous transplantation of cells into BALB/c nude mice. The U-251 cells stably transfected with Wnt3a expression plasmids and shFra1 were suspended at a density of 10 7 cells/ml and 100 μl was injected into the flank of each nude mouse (n=6). Ten days post-injection, cisplatin (5 mg/kg) was intraperitoneally administered every 3 days for 18 days. Seven days after subcutaneous transplantation, we measured the sizes of the growing tumours every 3 days for 21 days using the formula (W 2 × L). The mice were then killed and tumour weights were measured. All animal procedures were performed in compliance with the Guidelines for the Care and Use of Experimental Animals established by the Committee for Animal Experimentation of Hebei Medical University.
Immunohistochemistry
In total, 87 glioma tissue specimens were collected for the present study from 2005 to 2012 from The Second Hospital of Hebei Medical University and The Third Hospital of Hebei Medical University (Hebei, China). All specimens were fixed in 10% neutral formalin, embedded in paraffin and cut into 4-μm sections for immunohistochemical staining. The EnVision TM two-step method was used (DAKO, Hamburg, Germany), as well as the following antibodies: antibodies against Fra1 and β-catenin, were purchased from Cell Signaling Technology (Danvers, MA, U.S.A.). Prior to staining, sections were pretreated with microwaves for 18 min in a 0.01 M citrate buffer (pH 6.0) for antigen retrieval. 3,3 -Diaminobenzidine was used as a chromogen and 0.01 M PBS (pH 7.4) was substituted for primary antibodies as a negative control. To estimate the score for each slide, at least eight individual fields at 200× were chosen and 100 cancer cells were counted in each field. The immunostaining intensity was divided into four grades: 0, no expression; 1, mildly positive; 2, moderately positive and 3, markedly positive. The proportion of positive-staining cells was divided into five grades: 0, <10%; 1, 11-25%; 2, 26-50%; 3, 51-75% and 4, >75%. The staining results were assessed and confirmed by two independent investigators blinded to the clinical data. The percentage of positivity of the tumour cells and the staining intensities were then multiplied in order to generate the IHC score and graded as low expression (score 0-6) and high expression (score 7-12). Cases with a discrepancy in scores were discussed to obtain a consensus.
Statistical analysis
The software SPSS 13.0 was used in statistical analyses. Group distributions were performed with the Student's t test or one-way ANOVA. Pearson's correlation test was used in analysing the correlation. A value of P<0.05 was considered statistically significant.
Results
Activation of Wnt/β-catenin signalling induces EMT in glioma cells
It is noteworthy to determine the potential mechanisms of Wnt/β-catenin signalling in induction of glioma EMT. In U-251 and U-87 cells, decreased E-cadherin and ZO-1 accompanied by induction of Vimentin and Fibronectin at the mRNA level were observed in a Wnt3a dose-dependent manner ( Figure 1A ,B). Consistently, the protein levels of epithelial markers (E-cadherin and ZO-1) were repressed whereas mesenchymal markers (Vimentin and Fibronectin) increased after exogenous Wnt3a treatment ( Figure 1C ,D). Immunofluorescence showed that activation of Wnt/β-catenin signalling by Wnt3a promoted the expression of Vimentin, whereas blocking Wnt/β-catenin pathway by silencing β-catenin suppressed the mesenchymal marker in glioma cells ( Figure 1E ). As expected, knockdown of β-catenin attenuated Wnt3a induced up-regulation of Vimentin ( Figure 1F,G) . These results suggest a promotive effect of Wnt/β-catenin signalling on glioma EMT. Furthermore, several EMT-TFs were screened by QPCR and Western blot after activation of Wnt/β-catenin signalling. Although all the factors were elevated to different extents after Wnt3a treatment, both the mRNA and protein levels of Fra1 showed most significant up-regulation ( Figure 1H-J) . Therefore, Wnt/β-catenin signalling enhances the EMT of glioma cells, which may be accomplished by inducing EMT-TFs.
Wnt/β-catenin signalling activates the transcription of Fra1 in glioma cells
To further study the relationship between Wnt/β-catenin signalling and Fra1, glioma cells were exposed to specific inhibitors (LiCl and CHIR99021) for GSK-3β. As a result, activating Wnt/β-catenin signalling by targeting GSK-3β increased the mRNA and protein levels of Fra1 (Figure 2A,B) . Consistently, luciferase reporter assay showed that Wnt3a exposure increased the transcriptional activity of Fra1 promoter (-2500/+1) in a dose-dependent manner ( Figure 2C) , and the accumulation of Fra1 was further confirmed at the protein level ( Figure 2D ). Promoter analysis of human Fra1 gene predicted three potential Tcf/Lef-binding sites at the proximal region of Fra1 promoter, and then serial deletion constructs of the Fra1 gene promoter were analysed to identify the transcriptional regulatory elements responsive to Wnt/β-catenin signalling ( Figure 2E ). It was shown that the Fra1 promoter without the region between -1500 and -500 lost the ability to respond to Wnt3a treatment ( Figure 2F ). The DNA fragment (-1500/-500) contained two putative Tcf/Lef-binding sites. Mutaion in the latter site (Site3: -660/-647) obviously decreased the reporter activity induced by Wnt3a ( Figure 2G ). ChIP experiment further demonstrated that β-catenin/Tcf/Lef transcriptional complex directly bound to the Fra1 promoter approximately -700 bp upstream of the transcription start site and the binding was strengthened after Wnt3a stimulation ( Figure 2H,I ). These data suggest that Wnt/β-catenin signalling up-regulates Fra1 expression via transactivation.
Fra1 promotes Wnt3a-induced migration and invasion of glioma cancer cells
As expected, overexpression of Fra1 decreased the expressions of epithelial markers and increased the expressions of mesenchymal markers, whereas Fra1 knockdown had the opposite effect ( Figure 3A) . Considering increased invasion and migration as a classic feature of EMT, wound healing and cell invasion assays were performed to investigate the role of Fra1 in the EMT induced by Wnt/β-catenin signalling. Knockdown of either Fra1 or β-catenin weakened the migratory and invasive abilities of U-251cells ( Figure 3B,C) . In U-87 cells, knockdown of β-catenin impaired the promotive effect of Wnt3a on the aggressive phenotypes ( Figure 3D,E) . Moreover, the acquisition of migratory and invasive capacities in the U-251cells stimulated with Wnt3a was completely attenuated by Fra1 silencing (Figure 3F ,G). Based on Figure 1 , the expressions of EMT-TFs were analysed to understand the underlying molecular mechanism. As shown in Figure 3H -J, deprivation of Fra1 significantly disrupted the up-regulation of EMT-TFs induced by Wnt3a. The above findings reveal that up-regulation of Fra1 by Wnt3a is indispensible for the EMT induced by Wnt/β-catenin signalling in glioma cells.
Fra1 determines the cisplatin resistance of glioma cells induced by Wnt/β-catenin signalling in vitro and in vivo
In order to explore the role of Wnt/β-catenin/Fra1 axis in the chemoresistance of glioma cells, cisplatin resistance was analysed by in vitro and in vivo experiments. As shown in Figure 4A , the cisplatin resistance of glioma cells with Wnt3a stimulation was 1.67-fold higher than that of the control group, as measured by the IC50 values for cisplatin significantly associated with a better OS rate. The 'low' or 'high' of Fra1 and β-catenin levels was defined according to its cut-off value, which was defined as the median value of the cohort of patients tested; P<0.05 by log-rank test.
over 48 h treatment. Similarly, overexpression of Fra1 promoted cisplatin resistance, with IC50 increased 1.44-fold as compared with control ( Figure 4B ). However, knockdown of Fra1 sensitized glioma cells to cisplatin, with IC50 decreased to 69 percent ( Figure 4C) . Furthermore, the U-251 cells with stable Fra1 knockdown and Wnt3a overexpression were constructed and examined for cisplatin sensitivity. Wnt/β-catenin signalling activation decreased cisplatin-induced apoptosis in U-251 cells compared with control but failed to protect from apoptosis after Fra1 knockdown ( Figure 4D,E) , which was also observed in the U-87 cells with Fra1 siRNA transfection and Wnt3a treatment ( Figure 4F ). Xenograft tumour assay was taken to test whether such an effect would occur in vivo. The results showed that overexpressed Wnt3a increased resistance to cisplatin, and knockdown of Fra1 sensitized glioma cells to cisplatin. Notably, silence of Fra1 inhibited the protective effect of Wnt3a against cisplatin ( Figure 4G-I) . In summary, Wnt/β-catenin/Fra1 axis displays a critical role in the cisplatin resistance of giloma cells.
Abnormal Wnt/β-catenin/Fra1 signalling axis indicates a poor prognosis in glioma patients
Through analysing glioblastoma cancer microarray data sets on Oncomine, a higher Fra1 mRNA level was found in glioblastoma when compared with normal brain tissue ( Figure 5A) . Besides, the data from TCGA database (Glioblastoma: TCGA, Nature 2008 [20] ) were analysed to determine the correlation between Wnt3a and Fra1 at mRNA level in clinical glioma specimens by the cBioPortal platform and a positive correlation was observed ( Figure 5B ). Immunohistochemical staining was implemented to analyse the clinical relevance of Fra1 and β-catenin protein levels in 87 human glioma specimens. As shown in Table 1 , the β-catenin and Fra1 staining were positively correlated with WHO grade (P<0.05) but not with gender, age, tumour location, tumour diameter (P>0.05). Moreover, the Fra1 expression levels paralleled with the changes of β-catenin in the glioma cases as shown by immunohistochemical analysis (P<0.05) ( Figure 5C ). The 3-year overall survival (OS) rate of the Fra1 and β-catenin double-high expression group was significantly lower than that of the Fra1 and β-catenin double-low expression group (15.8% compared with 45.8%, P=0.003) ( Figure 5D ). These data suggest that aberrant activation of Wnt/β-catenin/Fra1 signalling axis drives glioma progression and indicates a poor prognosis.
Discussion
As the canonical Wnt pathway, β-catenin-dependent pathway plays an important role in many biological progresses such as tissue homoeostasis, embryonic development and tumorigenesis. In recent studies, it has been reported that aberrant activation of Wnt/β-catenin signalling contributed to glioma development [21] . The evidence based on clinical glioma specimens also showed the up-regulation of β-catenin and Tcf-4 in cancer tissues compared with normal brain [22] . The siRNA induced knockdown of Lef1 or β-catenin suppressed cell proliferation and invasion as well as promoting apoptosis in glioma cells [23, 24] . Besides, various target genes result in the multifunction of Wnt/β-catenin signalling in cancer development. The high invasive ability of glioma cancer to degrade extracellular matrix (ECM) depends on MMPs, which are the crucial genes regulated by Wnt signalling [25] . Other target genes including cyclinD1 and c-myc are required for cellular proliferation in glioma [26] . Here, we found that the EMT-TF, Fra1, which were transactivated by β-catenin/Tcf/Lef complex, promoted the EMT programme induced by Wnt/β-catenin signalling in glioma cells. Knockdown of Fra1 decreased Wnt3a-induced EMT markers as well as migration and invasion of glioma cells, which suggested Fra1 as a key factor to form a cross-talk between Wnt pathway and EMT transition. Interestingly, we observed that Wnt/β-catenin/Fra1 axis conferred the cisplatin resistance of giloma in vitro and in vivo. Further analysis of clinical specimens revealed that aberrant expression of Fra1 or β-catenin in glioma tissues indicated a poor prognosis. The activator protein-1 complex (AP1) consisting of homo-or heterodimers of Fos, Jun, ATF and MAF family members has been implicated as central activator of tumour cell invasion. Among them, Fra1 is one of the most frequently aberrant expressed AP1 proteins in a variety of tumour types including glioma [27] [28] [29] . In previous studies, Fra1 was explored as a key EMT switch and its ability to promote migration and invasion was found in many cancer types [30, 31] . In addition, up-regulation of Fra1 mediates the resistance to anticancer drug nimustine (ACNU) in glioma cells [32] . More and more target genes of Fra1 have been demonstrated to explain the roles of the important regulator in biological processes. The EMT-TFs such as Snail, Slug and Zeb1 along with the EMT markers including Vimentin, MMP2 and MMP9 are the classical genes regulated by Fra1 [12] . Interestingly, some Fra1-induced factors like Zeb1 and MMPs could also be regulated by β-catenin, which indicated that Fra1 might serve as a node factor in Wnt/β-catenin pathway [33, 34] . In the present work, we observed that activating Wnt/β-catenin pathway increased EMT-TFs, whereas knockdown of Fra1 reversed the effect in glioma cells. However, other proteins involved in Wnt/β-catenin/Fra1 axis deserve to be investigated in the future.
In studies with GBM-derived cell lines, activation of the canonical Wnt/β-catenin pathway could modulate a set of EMT-TFs including Twist1 and Zeb1/2 [8] . Twist1 and Zeb1/2 are the cardinal activators of EMT in glioma, which have been well studied. Initial reports demonstrated that Twist1 was overexpressed in MG and enhanced GBM invasion [35] . Knockdown of Twist1 impaired the capacities of migration and invasion as well as sphere formation in GBM [9] . Examination of specimens derived from glioblastoma patients showed significantly higher Zeb2 level with early relapse and fast tumour progression [36] . In our study, the inductions of Twist1 and Zeb1/2 by activating Wnt/β-catenin signalling were also observed. However, by comparison, alteration of Fra1 expression was the most remarkable among these EMT-TFs. Interestingly, aberrant expressions of β-catenin and Fra1 were predominant at the invasive front of the tumour [8, 37] . Therefore, the roles of Wnt/β-catenin/Fra1 pathway in activating the growth of tumour bud need further investigations.
In conclusion, our findings demonstrate that Wnt/β-catenin signalling can induce the EMT programme of glioma cells by up-regulating Fra1 expression. Further results reveal that Wnt/β-catenin signalling activates the transcription of Fra1 by directly binding β-catenin/Tcf/Lef transcriptional complex to the WRE located at the proximal region of Fra1 promoter. Phenotype experiments and clinical analysis support the critical role of Fra1 in mediating the glioma aggressiveness induced by Wnt/β-catenin signalling. Therefore, the correlation between Wnt/β-catenin signalling and Fra1 raises the possibility of developing novel biomarkers and therapeutic targets for glioma.
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